Four wholly owned drugs will be Phase 1b/Phase 2 in 2025
DRAGONFLY's mission is to revolutionize disease treatment by inventing natural killer cell-based therapies for vastly improved patient outcomes
We build drugs in autoimmune disease, oncology, fibrosis, neuro-inflammation, neurology, and beyond.
In collaboration with AbbVie, BMS, Gilead and Merck, our novel TriNKET® and CYTOKINE platforms have generated 11 Drug Candidates that have been handed off to partners.
Engaging the Immune
System to Fight Disease
Dragonfly
Latest News
Dragonfly to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET®, at SITC
The company today announced the company will deliver poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Conference, highlighting preclinical data supporting two clinical-stage assets, DF6215, its engineered IL-2 cytokine, and DF9001, its EGFR-targeting TriNKET, for the treatment of advanced solid tumors.
Our Collaborations
DRAGONFLY is a distinctively effective pharma partner.
Dragonfly rapidly develops drugs with our pharma partners in expanding fields from autoimmune disease and oncology, to neuro-inflammation, neuromuscular disease, virology, and beyond.
Our Platform
TriNKET®
CYTOKINE
Two Proprietary Platforms
DRAGONFLY is a clinical-stage biotech that has developed a deep portfolio of drugs in autoimmune disease and oncology, built on two unique platforms: first-in-class tri-specific immune engagers (“TriNKET®s”) and best-in-class CYTOKINEs – each with lead drugs in the clinic with encouraging results.
Growing the
Pipeline for Patients
In addition to a set of advanced programs in the clinic or handed off to our pharma partners, DRAGONFLY is developing 30+ TriNKETs® and multiple CYTOKINES across a broad range of fields, including autoimmune and inflammatory diseases, fibrosis, neurology, infectious disease, and oncology.
DRAGONFLY's pipeline is rapidly growing in a number of
therapeutic areas of critical patient need.
